Pfizer and its partner Avillion LLP have announced the results from the BFORE clinical study.
According to the results released by Pfizer and Avillion, the Phase 3 trial established BOSULIF’s superiority over imatinib in patients who have chronic phase Philadelphia chromosome positive (PH+) chronic myeloid leukemia (CML).
“Since its approval, the efficacy and distinct tolerability profile of BOSULIF has provided an important treatment option for patients with Ph+ CML who are resistant or intolerant to prior therapy. The positive outcome of the BFORE study represents a key step in potentially broadening treatment options for patients in the first-line setting,” Pfizer Global Product Development Chief Development Officer Dr. Mace Rothenberg said.
He said this is an important milestone for Pfizer’s emerging hematology portfolio as they work to develop new treatments for patients with acute and chronic hematologic malignancies.
“This successful partnership between Pfizer and Avillion is good news for CML patients because additional first-line treatment options allow physicians to tailor therapy based on individual patient considerations,” Avillion CEO Dr. Allison Jeynes-Ellis said. “The outcome of this partnership reinforces our belief in the potential of our innovative business model for the co-development and partnership of late-stage clinical candidates.”